Drug Type Monoclonal antibody |
Synonyms 格鲁塔珠单抗, GMA-102, GMA-102/105 + [2] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | China | 20 Aug 2021 | |
Obesity | Phase 3 | China | 01 Nov 2020 |
Phase 1/2 | - | uiiqumxwop(qoueseinfy) = 80mg固定剂量组和80mg剂量滴定组的所有不良反应均为轻度,不良反应多为胃肠道反应,常发生于首次给药后,随着给药逐渐减轻。 jsudfmhhxb (bhomdqlxor ) View more | Positive | 26 Dec 2022 |